36.19
36.19 (0%)
As of Apr 17, 2025
Exelixis, Inc. [EXEL]
Source:
Company Overview
Exelixis, Inc. is an oncology company innovating next-generation medicines and combination regimens at the forefront of cancer care. We have produced four marketed pharmaceutical products, two of which are formulations of our flagship molecule, cabozantinib, and we are steadily advancing and evolving our product pipeline portfolio, including our lead investigational asset, zanzalintinib, currently the focus of an extensive late-stage clinical development program.
| Country | United States |
| Headquarters | alameda, california |
| Phone Number | (650) 837-7000 |
| Industry | manufacturing |
| CEO | Michael M. Morrissey |
| Website | www.exelixis.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $2,168.7 |
| Operating Profit | $604.6 |
| Net Income | $521.3 |
| Net Cash | $-45.6 |
Profit Ratios
| Gross Margin | $2,092.5 |
| Operating Margin | 27.9 |
| Profit as % of Revenues | 401.4% |
| Profit as % of Assets | 17.7% |
| Profit as % of Stockholder Equity | 23.2% |
Management Effectiveness
| Return on Equity | 23.2% |
| Return on Assets | 17.7% |
| Turnover Ratio | 73.6% |
| EBITA | $604.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $2,947.7 |
| Total Liabilities | $703.5 |
| Operating Cash Flow | $700 |
| Investing Cash Flow | $-116.8 |
| Financing Cash Flow | $-628.8 |
